Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine DOI Creative Commons
Saif Khan,

Suresh Babu Jandrajupalli,

Nashwa Zaki Ali Bushara

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(24), P. 2126 - 2126

Published: Dec. 22, 2024

Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors PARP offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug conjugates (ADCs) sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with Trop-2-targeting antibody via pH-sensitive linking moiety, achieving good drug:antibody ratio. In phase I-II study involving metastatic TNBC (mTNBC) individuals, achieved overall response rate 33.3% median period 7.7 months. The III ASCENT trial demonstrated SG’s efficacy in relapsed or refractory TNBC, improving progression-free survival compared chemotherapy. Common side effects include neutropenia, nausea, fatigue. This article highlights clinical potential, pharmacokinetics, safety profile, resistance mechanisms along key ongoing trials, emphasizing role managing mTNBC, especially third-line therapy. review also discusses current strategies for adverse reactions sequencing ADC treatments practice, predicted basis resistance. optimal relative other ADCs, such as trastuzumab deruxtecan T-DXd, evolving question, newer agents distinct action profiles enter field. Further research is essential establish evidence-based addressing disease progression post-ADC

Language: Английский

Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer DOI Open Access

Josephine B. Oehler,

Weranga Rajapaksha, Hugo Albrecht

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(7), P. 723 - 723

Published: July 4, 2024

Breast cancer remains the most prevalent among women worldwide, driving urgent need for innovative approaches to diagnosis and treatment. This review highlights pivotal role of nanoparticles in revolutionizing breast management through advancements interconnected including targeted therapy, imaging, personalized medicine. Nanoparticles, with their unique physicochemical properties, have shown significant promise addressing current treatment limitations such as drug resistance nonspecific systemic distribution. Applications range from enhancing delivery systems sustained release developing diagnostic tools early precise detection metastases. Moreover, integration into photothermal therapy synergistic use existing treatments, immunotherapy, illustrate transformative potential care. However, journey towards clinical adoption is fraught challenges, chemical feasibility, biodistribution, efficacy, safety concerns, scalability, regulatory hurdles. delves state nanoparticle research, applications diagnosis, obstacles that must be overcome integration.

Language: Английский

Citations

18
Metabolic dysfunction-associated steatotic liver disease: A sexually dimorphic disease and breast and gynecological cancer DOI
Xinrong Zhang,

Mindie H. Nguyen

Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 156190 - 156190

Published: March 1, 2025

Language: Английский

Citations

1
Hypomethylating agents as emerging therapeutics for triple-negative breast cancer DOI

Nik Mohd Asri Nik Amirah Auni,

Norhanani Mohd Redzwan, Agustine Nengsih Fauzi

et al.

Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123403 - 123403

Published: Jan. 1, 2025

Language: Английский

Citations

0
A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer DOI
Reiki Nishimura, Yasuaki Sagara,

Reiko Mitsueda

et al.

Breast Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 18, 2025

Language: Английский

Citations

0
Development of a prognostic model based on the ceRNA network in Triple-Negative Breast cancer DOI Creative Commons

Yimin Zhu,

Jiayu Wang, Binghe Xu

et al.

PeerJ, Journal Year: 2025, Volume and Issue: 13, P. e19063 - e19063

Published: Feb. 27, 2025

Background Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis. Although circular RNAs (circRNAs) have been implicated in progression, their roles TNBC remain poorly understood. In this study, we aimed to develop prognostic model for by constructing competing endogenous RNA (ceRNA) network. This network integrates circRNAs, long noncoding (lncRNAs), microRNAs (miRNAs), and messenger (mRNAs) identify potential biomarkers therapeutic targets improving clinical outcomes. Methods Differentially expressed lncRNAs, mRNAs were identified from GEO datasets (144 samples: 94 50 normal tissues). A ceRNA was constructed, key genes validated using The Cancer Genome Atlas (TCGA) dataset (115 113 para-cancer Multivariate Cox regression analysis performed model, Gene Set Enrichment Analysis (GSEA) associated pathways. Results Nine ( SH3BGRL2 , CA12 LRP8 NAV3 GFRA1 DCDC2 CDC7 ABAT NPTX1 ) as factors the which demonstrated area under curve (AUC) of 0.90. Patients classified high-risk patients exhibited significantly shorter overall survival (median OS: 8.12 years vs . 9.51 years, P < 0.01). mitogen-activated protein kinase (MAPK) signaling pathway regulatory pathway, circRNAs (hsa_circ_0005455, hsa_circ_000632, hsa_circ_0001666, hsa_circ_0000069) regulating expression. Conclusion study developed novel based on analysis, highlighting critical role MAPK progression. These findings offer valuable insights into prognosis reveal promising patient

Language: Английский

Citations

0
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells DOI Creative Commons
Tânia Moura, Paula Laranjeira, Olga Caramelo

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(3), P. 143 - 143

Published: Feb. 28, 2025

Breast cancer is the most common type of in women and second leading cause death by cancer. Despite recent advances, mortality rate remains high, underlining need to develop new therapeutic approaches. The complex interaction between cells tumor microenvironment (TME) crucial determining progression, therapy response, patient prognosis. Understanding role immune carcinogenesis progression can help improve targeted options, increasing likelihood a favorable Therefore, this review aims critically analyze cells, emphasizing clinical implications. Additionally, we explore advances immunotherapies, with focus on checkpoint inhibitors.

Language: Английский

Citations

0
Therapeutic implications of Epirubicin-induced miRNA-22 and miRNA-331 upregulation on cell viability and metastatic potential in triple-negative breast cancer DOI
Somayeh Farahmand, Saber SamadiAfshar, Mahsa Khalili

et al.

Human Gene, Journal Year: 2025, Volume and Issue: unknown, P. 201396 - 201396

Published: Feb. 1, 2025

Language: Английский

Citations

0
Carcinoma Metaplásico de Mama: Diagnóstico e Abordagem Multidisciplinar em Caso de Subtipo Raro DOI Creative Commons
Rita D. Brandão, Mateus Cardoso Oliveira,

Rafael Isaque Lira do Nascimento

et al.

Revista Brasileira de Cancerologia, Journal Year: 2025, Volume and Issue: 71(2), P. e - 024981

Published: March 6, 2025

Introdução: O carcinoma metaplásico da mama (CMM) é um subtipo raro e agressivo de câncer mama, caracterizado pela presença dois tipos celulares, geralmente, epiteliais mesenquimais. Com menos 1% incidência nos cânceres invasivos compartilhasemelhanças com o triplo-negativo, mas apresenta maior resistência à quimioterapia pior prognóstico. Relato Caso: Paciente do sexo feminino, 66 anos, foi encaminhada após alterações em exames imagem. A mamografia revelou uma lesão nodular namama esquerda, a ultrassonografia demonstrou cistos características suspeitas. punção aspirativa por agulha fina (PAAF) core biopsy indicaram, inicialmente, “condições fibrocísticas benignas”. No entanto, setorectomia análise histopatológica, diagnósticofoi “carcinoma adenoescamoso” associado papilífero intraductal ductal in situ”. paciente submetida nova cirurgia (quadrantectomia) para ampliação das margens cirúrgicas biópsia linfonodos ausência comprometimentoneoplásico. tratamento incluiu adjuvante. Conclusão:Este relato caso destaca raridade CMM, complexidade diagnóstico manejo dessa condição. colaboração multidisciplinar entre oncologistas, radiologistas, patologistas cirurgiões fundamental adequado. acompanhamento rigoroso terapia adjuvante são essenciais melhorar prognóstico desses pacientes.

Citations

0
PFDN1 silencing disrupts critical cancer pathways in triple-negative breast cancer: investigating migration, cell cycle, and apoptosis as a new target therapy DOI

Abdulrahman M. Alokda,

Ahmed Soffar,

Amany I. Yousef

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Language: Английский

Citations

0
Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives DOI Creative Commons
Zhenjun Huang, Qing Peng,

Luhui Mao

et al.

MedComm – Future Medicine, Journal Year: 2025, Volume and Issue: 4(1)

Published: March 1, 2025

ABSTRACT Triple‐negative breast cancer (TNBC) is a highly aggressive subtype of cancer, characterized by poor prognosis and limited therapeutic options. Although neoadjuvant chemotherapy (NACT) remains the established treatment approach, its suboptimal efficacy associated with TNBC highlight urgent need for optimized strategies to improve pathological complete response (pCR) rates. This review provides comprehensive overview recent advancements in TNBC, emphasizing pivotal breakthroughs ongoing pursuit innovative approaches enhance precision medicine. It emphasizes clinical value platinum‐based agents, such as carboplatin cisplatin, which have shown significant improvements pCR rates, particularly patients BRCA mutations. Additionally, explores progress targeted therapies, including PARP inhibitors, AKT Antiangiogenic showcasing their potential personalized approaches. The integration immunotherapy, immune checkpoint inhibitor like pembrolizumab atezolizumab, has demonstrated substantial high‐risk cases. Future research priorities include refining biomarker‐driven strategies, optimizing combinations, developing antibody‐drug conjugates (ADCs) targeting TROP2 other biomarkers, reducing treatment‐related toxicity develop safer therapies. Furthermore, artificial intelligence also emerged transformative tool predicting decision‐making TNBC. These aim long‐term outcomes quality life

Language: Английский

Citations

0